Charlotte Eye Ear Nose and Throat Assciates, PA Report issue

Academic/Hospital Phase 4

Organization Overview

First Clinical Trial
2016
NCT02858076
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Alternative names

Charlotte Eye, Ear, Nose and Throat Assoc., PA

Active Ingredients

Drugs in Phase 4 Trials (1)

aflibercept (zaltrap) (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diabetic Retinopathy (Phase 3)

Edema (Phase 4)

Hemorrhage (Phase 3)

Macular Edema (Phase 4)

Retinal Diseases (Phase 3)

Vitreous Hemorrhage (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 2
  • # of Trial APIs: 1